User:Mr. Ibrahem/Fluticasone furoate/vilanterol

Fluticasone furoate/vilanterol (FF/VI), sold under the brand name Breo Ellipta among others, is a combination medication used for long-term treatment of chronic obstructive pulmonary disease (COPD) and asthma. In Europe it as a second-line therapy. It is used by breathing it in through the mouth.

Common side effects include thrush, headache, upper respiratory tract infection, cough, and throat pain. Other side effects may include pneumonia, bronchospasm, glaucoma, and low potassium. It contains fluticasone furoate, a corticosteroid, and vilanterol, a long-acting β2 agonist (LABA). There are concerns that a LABA alone may worsen outcomes in asthma.

The combination was approved for medical use in the United States and Europe in 2013. It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol. It is available as a generic medication. In the United States it costs about 160 USD for 60 doses as of 2023. The amount in the United Kingdom costs the NHS about £44. In 2020, it was the 115th most commonly prescribed medication in the United States, with more than 5million prescriptions.